文献速递心脑血管急症消化、代谢与肾脏急症

氯卡色林在超重或肥胖患者中的心血管安全性

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
PubMed 文献 · N Engl J Med · 2018-08-26
一句话结论超重或肥胖且伴动脉粥样硬化性心血管病或多重心血管危险因素者,氯卡色林10 mg每日两次不增加主要心血管事件,但严重低血糖例数多于安慰剂。

CAMELLIA-TIMI 61随机将12000例超重或肥胖且伴动脉粥样硬化性心血管病或多重心血管危险因素的患者分配至氯卡色林10 mg每日两次或安慰剂。1年时体重下降至少5%者在氯卡色林组为5135例中的1986例(38.7%),安慰剂组为5083例中的883例(17.4%)(OR 3.01,95%CI 2.74–3.30,P<0.001)。中位随访3.3年,主要安全性终点(心血管死亡、心肌梗死或卒中)年发生率氯卡色林组2.0%、安慰剂组2.1%(HR 0.99,95%CI 0.85–1.14,非劣效P<0.001);扩展主要心血管事件年发生率分别为4.1%和4.2%(HR 0.97,95%CI 0.87–1.07,P=0.55)。特别关注的不良事件两组总体相似,但氯卡色林组严重低血糖例数更多(13例 vs 4例,P=0.04)。

要点

  • 主要安全性终点年发生率氯卡色林组2.0% vs 安慰剂组2.1%,HR 0.99(95%CI 0.85–1.14),非劣效P<0.001。
  • 扩展主要心血管事件年发生率氯卡色林组4.1% vs 安慰剂组4.2%,HR 0.97(95%CI 0.87–1.07),P=0.55。
  • 1年体重下降至少5%者氯卡色林组38.7%(1986/5135) vs 安慰剂组17.4%(883/5083),OR 3.01(95%CI 2.74–3.30)。
  • 严重低血糖氯卡色林组13例 vs 安慰剂组4例(P=0.04),为特别关注的不良事件中两组唯一有差异者。
  • 中位随访3.3年,氯卡色林组心脏危险因素(血压、心率、血糖控制、血脂)略优于安慰剂组。

适用人群与场景

  • 超重或肥胖且伴动脉粥样硬化性心血管病或多重心血管危险因素的患者,共12000例随机分组。

处置流程与药物剂量

  • 氯卡色林10 mg每日两次口服,对照为安慰剂。

红旗征与不能漏的情况

  • 严重低血糖:氯卡色林组13例 vs 安慰剂组4例(P=0.04),为特别关注的不良事件。

研究设计与关键结果

  • 研究类型:随机对照试验(CAMELLIA-TIMI 61,NCT02019264),12000例超重或肥胖且伴动脉粥样硬化性心血管病或多重心血管危险因素的患者,氯卡色林10 mg每日两次 vs 安慰剂。
  • 1年体重下降至少5%:氯卡色林组1986/5135(38.7%) vs 安慰剂组883/5083(17.4%),OR 3.01(95%CI 2.74–3.30),P<0.001。
  • 主要安全性终点(心血管死亡、心肌梗死或卒中)年发生率:氯卡色林组2.0% vs 安慰剂组2.1%,HR 0.99(95%CI 0.85–1.14),非劣效P<0.001。
  • 扩展主要心血管事件(主要心血管事件、心力衰竭、不稳定性心绞痛住院或冠状动脉血运重建)年发生率:氯卡色林组4.1% vs 安慰剂组4.2%,HR 0.97(95%CI 0.87–1.07),P=0.55。
  • 中位随访3.3年;氯卡色林组心脏危险因素(包括血压、心率、血糖控制、血脂)略优于安慰剂组。
  • 特别关注的不良事件不常见且两组总体相似,唯严重低血糖氯卡色林组13例 vs 安慰剂组4例(P=0.04)。

证据类型、等级与局限

  • 证据类型:随机对照试验(CAMELLIA-TIMI 61)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对超重或肥胖且伴动脉粥样硬化性心血管病或多重心血管危险因素的患者,氯卡色林10 mg每日两次可在不增加主要心血管事件的前提下促进持续体重下降。
  • 使用氯卡色林者需注意严重低血糖,该研究中氯卡色林组13例 vs 安慰剂组4例(P=0.04)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined.

METHODS: We randomly assigned 12,000 overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors to receive either lorcaserin (10 mg twice daily) or placebo. The primary safety outcome of major cardiovascular events (a composite of cardiovascular death, myocardial infarction, or stroke) was assessed at an interim analysis to exclude a noninferiority boundary of 1.4. If noninferiority was met, the primary cardiovascular efficacy outcome (a composite of major cardiovascular events, heart failure, hospitalization for unstable angina, or coronary revascularization [extended major cardiovascular events]) was assessed for superiority at the end of the trial.

RESULTS: At 1 year, weight loss of at least 5% had occurred in 1986 of 5135 patients (38.7%) in the lorcaserin group and in 883 of 5083 (17.4%) in the placebo group (odds ratio, 3.01; 95% confidence interval [CI], 2.74 to 3.30; P<0.001). Patients in the lorcaserin group had slightly better values with respect to cardiac risk factors (including blood pressure, heart rate, glycemic control, and lipids) than those in the placebo group. During a median follow-up of 3.3 years, the rate of the primary safety outcome was 2.0% per year in the lorcaserin group and 2.1% per year in the placebo group (hazard ratio, 0.99; 95% CI, 0.85 to 1.14; P<0.001 for noninferiority); the rate of extended major cardiovascular events was 4.1% per year and 4.2% per year, respectively (hazard ratio, 0.97; 95% CI, 0.87 to 1.07; P=0.55). Adverse events of special interest were uncommon, and the rates were generally similar in the two groups, except for a higher number of patients with serious hypoglycemia in the lorcaserin group (13 vs. 4, P=0.04).

CONCLUSIONS: In a high-risk population of overweight or obese patients, lorcaserin facilitated sustained weight loss without a higher rate of major cardiovascular events than that with placebo. (Funded by Eisai; CAMELLIA-TIMI 61 ClinicalTrials.gov number, NCT02019264 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018. PMID: 30145941. doi:10.1056/NEJMoa1808721

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。